Framework agreement for the purchase of Casgevy (exagamglogene autotemcel)

The purpose of this framework agreement is to enable Amgros's stakeholder hospital pharmacies to be supplied with the medicinal product Casgevy (exagamglogene autotemcel). The Capital Region's hospital pharmacy will also make purchases for resale to Greenland and the Faroe Islands. Casgevy is a groundbreaking gene therapy used to treat sickle cell disease and beta-thalassemia. This framework agreement aims to ensure a consistent and efficient supply chain for this advanced and potentially high-cost medication. It will establish the terms and conditions under which hospital pharmacies can procure Casgevy, likely including pricing, ordering procedures, and delivery schedules. The involvement of Amgros, a coordinating purchasing organization for Danish hospitals, highlights the strategic importance of securing access to this innovative treatment.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.